Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

Evolution of the individualized treatment landscape for advanced NSCLC

IASLC Asia Pacific Lung Cancer Conference (APLCC) 2016 – Independent satellite symposium

Chaired by Tony Mok with Ross Soo and Giorgio Scagliotti

Held on Friday 13th May 2016, Chiang Mai, Thailand

The expert Faculty guided us through this complexity by placing the latest developments in advanced NSCLC into the context of treatment. They provided their insights into how we can use our biological knowledge not only to improve treatment pathways, but also to maximize treatment outcomes by understanding different approaches. The scientific summary includes questions that were put to the audience by the Chair, Professor Tony Mok.

Scientific summary


Here we provide a scientific summary including a documented account of the symposium presentations and associated discussions, video highlights, and also questions that were put to the audience by the Chair, Professor Tony Mok, from The Chinese University of Hong Kong. The key topics covered in the scientific summary are:

  • How best to manage patients with nonsquamous cell NSCLC without EGFR/ALK mutations – Dr Ross Soo.
  • Therapeutic options for patients with advanced squamous NSCLC – Professor Giorgio Scagliotti.

© Springer Healthcare IME

Learning objectives

After attending this symposium, learners will be able to:

  • Assess the new treatment paradigms for non-mutated advanced and metastatic non-squamous NSCLC, and explain how to best apply them to individualized patient care in their daily practice.
  • Describe the rapidly expanding and complex range of treatment options for advanced and metastatic squamous NSCLC, and explain how to best apply them to individualized patient care in their daily practice.

Faculty bios

Educational grant

This program is made possible thanks to independent educational sponsorship from Eli Lilly and Company.

Produced by Springer Healthcare IME.

Contact us

Email: IME@springer.com
Telephone +44 (0) 203 192 2023
Springer Healthcare IME
The Campus, 4 Crinan Street
London, N1 9XW, UK